STUDY TITLE: Microsatellite Stable Colorectal Cancer with Radiographic Occult Molecular Residual Disease Treated with Botensilimab (AGEN1181; Bot) plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)
NCT ID: TBD
This is an upcoming trial to study the effect of a botensilimab and balstilimab regimen in CRC patients with MRD after definitive standard-of-care therapy.
Status: Not yet Recruiting
Key Eligibility Criteria
- Patients with confirmed colorectal adenocarcinoma
- Patients must:
- have undergone a complete surgical resection for stages II and III colon or rectal cancer and completed all planned adjuvant therapies
- have no radiographic evidence of disease within 28 days before or after a positive ctDNA assay